214 related articles for article (PubMed ID: 30103321)
1. Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study.
Segovia F; Gómez-Río M; Sánchez-Vañó R; Górriz JM; Ramírez J; Triviño-Ibáñez E; Carnero-Pardo C; Martínez-Lozano MD; Sopena-Novales P
J Alzheimers Dis; 2018; 65(3):765-779. PubMed ID: 30103321
[TBL] [Abstract][Full Text] [Related]
2. Early-Phase 18F-Florbetaben PET as an Alternative Modality for 18F-FDG PET.
Son SH; Kang K; Ko PW; Lee HW; Lee SW; Ahn BC; Lee J; Yoon U; Jeong SY
Clin Nucl Med; 2020 Jan; 45(1):e8-e14. PubMed ID: 31524679
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of early-phase [
Daerr S; Brendel M; Zach C; Mille E; Schilling D; Zacherl MJ; Bürger K; Danek A; Pogarell O; Schildan A; Patt M; Barthel H; Sabri O; Bartenstein P; Rominger A
Neuroimage Clin; 2017; 14():77-86. PubMed ID: 28138429
[TBL] [Abstract][Full Text] [Related]
4. [Amyloid positron-emission-tomography with [
Schönecker S; Prix C; Raiser T; Ackl N; Wlasich E; Stenglein-Krapf G; Mille E; Brendel M; Sabri O; Patt M; Barthel H; Bartenstein P; Levin J; Rominger A; Danek A
Nervenarzt; 2017 Feb; 88(2):156-161. PubMed ID: 27913818
[TBL] [Abstract][Full Text] [Related]
5. Dual Time-Point [18F]Florbetaben PET Delivers Dual Biomarker Information in Mild Cognitive Impairment and Alzheimer's Disease.
Florek L; Tiepolt S; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Luthardt J; Sattler B; Patt M; Hoffmann KT; Villringer A; Classen J; Gertz HJ; Sabri O; Barthel H
J Alzheimers Dis; 2018; 66(3):1105-1116. PubMed ID: 30400095
[TBL] [Abstract][Full Text] [Related]
6. Coupled Imaging with [
Chiaravalloti A; Castellano AE; Ricci M; Barbagallo G; Sannino P; Ursini F; Karalis G; Schillaci O
Mol Imaging Biol; 2018 Aug; 20(4):659-666. PubMed ID: 29404839
[TBL] [Abstract][Full Text] [Related]
7. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
8. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Body Mass Index, ApoE4 Status, and PET-Based Amyloid and Neurodegeneration Markers in Amyloid-Positive Subjects with Normal Cognition or Mild Cognitive Impairment.
Blautzik J; Kotz S; Brendel M; Sauerbeck J; Vettermann F; Winter Y; Bartenstein P; Ishii K; Rominger A;
J Alzheimers Dis; 2018; 65(3):781-791. PubMed ID: 28697560
[TBL] [Abstract][Full Text] [Related]
10. Clinical Relevance of [
Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
[TBL] [Abstract][Full Text] [Related]
11. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
[TBL] [Abstract][Full Text] [Related]
12. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET.
Brendel M; Schnabel J; Schönecker S; Wagner L; Brendel E; Meyer-Wilmes J; Unterrainer M; Schildan A; Patt M; Prix C; Ackl N; Catak C; Pogarell O; Levin J; Danek A; Buerger K; Bartenstein P; Barthel H; Sabri O; Rominger A
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2239-2248. PubMed ID: 28932894
[TBL] [Abstract][Full Text] [Related]
13. High Correlation of Static First-Minute-Frame (FMF) PET Imaging after
Seiffert AP; Gómez-Grande A; Villarejo-Galende A; González-Sánchez M; Bueno H; Gómez EJ; Sánchez-González P
Sensors (Basel); 2021 Jul; 21(15):. PubMed ID: 34372416
[TBL] [Abstract][Full Text] [Related]
14. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
Peretti DE; Vállez García D; Reesink FE; van der Goot T; De Deyn PP; de Jong BM; Dierckx RAJO; Boellaard R
PLoS One; 2019; 14(1):e0211000. PubMed ID: 30653612
[TBL] [Abstract][Full Text] [Related]
15. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
[TBL] [Abstract][Full Text] [Related]
16. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.
Ong KT; Villemagne VL; Bahar-Fuchs A; Lamb F; Langdon N; Catafau AM; Stephens AW; Seibyl J; Dinkelborg LM; Reininger CB; Putz B; Rohde B; Masters CL; Rowe CC
J Neurol Neurosurg Psychiatry; 2015 Apr; 86(4):431-6. PubMed ID: 24970906
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
[TBL] [Abstract][Full Text] [Related]
18. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.
Kemppainen N; Joutsa J; Johansson J; Scheinin NM; Någren K; Rokka J; Parkkola R; Rinne JO
J Alzheimers Dis; 2015; 48(1):123-33. PubMed ID: 26401934
[TBL] [Abstract][Full Text] [Related]
20. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
